Towards an Arthritis Flare-Responsive Drug Delivery System
Abstract
Local delivery of therapeutics for the treatment of inflammatory arthritis (IA) is limited by short intra-articular half-lives. Since IA severity often fluctuates over time, a local drug delivery method that titrates drug release to arthritis activity would represent an attractiveparadigm in IA therapy. Here we report the development of a hydrogel platform that exhibits disassembly and drug release controlled by the concentration of enzymes expressed during arthritis flares. In vitro, hydrogel loaded with triamcinolone acetonide (TA) releases drug on demand upon exposure to enzymes or synovial fluid from patients with rheumatoid arthritis. In arthritic mice, hydrogel loaded with a fluorescent dye demonstrates flare-dependent disassembly measured as loss of fluorescence. Moreover, a single dose of TA-loaded hydrogel but not the equivalent dose of locally injected free TA reduces arthritis activity in the injected paw. Together, our data suggest flare-responsive hydrogel as a promising next-generation drug delivery approach for the treatment of IA.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 03, 2018
- Accession Number
- AD1095253
Entities
People
- Antonios O. Aliprantis
- Ellen M Gravallese
- Jeffrey M. Karp
- Jing Yan
- Joerg Ermann
- Julian Amirault
- Kai V. Slaughter
- Logan Riegel
- Michael Valic
- Nicholas E Sherman
- Nitan Joshi
- Oren Levy
- Oscar R Miranda
- Praveen K Vemula
- Sachin Bhagchandani
- Seth Levy
- Tan S Rui
- Xueyin He
- Yufeng Wang